Design Therapeutics (DSGN) Income from Continuing Operations (2020 - 2026)
Design Therapeutics (DSGN) reported Income from Continuing Operations of 20992000.0 for Q1 2026, down 3.63% on a YoY basis from 21783501.64 in Q1 2025, and down 15.45% sequentially from 18183000.0 in Q4 2025.
Design Therapeutics (DSGN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Income from Continuing Operations data on file, last reported at 20992000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 3.63% year-over-year to 20992000.0; the trailing twelve-month figure through Mar 2026 stood at 80262000.0 (down 21.88% YoY), and the FY2025 full-year result was 53792539000.0, down 173.08% from the prior year.
- Income from Continuing Operations slipped to 20992000.0 in Q1 2026, from 18183000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 13299000.0 in Q1 2024 to a low of 10552338000.0 in Q4 2022.
- A 5-year average of 703733000.0 and a median of 20256000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 92733.1% in 2022 and soared 98.55% in 2024, its largest moves.
- Tracing DSGN's Income from Continuing Operations over 5 years: stood at 10552338000.0 in 2022, then surged by 89.37% to 1121426000.0 in 2023, then soared by 98.55% to 16288000.0 in 2024, then slipped by 11.63% to 18183000.0 in 2025, then fell by 15.45% to 20992000.0 in 2026.
- Business Quant data shows DSGN's Income from Continuing Operations at 20992000.0 in Q1 2026, 18183000.0 in Q4 2025, and 19265000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Design Therapeutics | 725.54 Mn | 502.72 Mn | - | -20.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.99 Mn |
| Dec 31, 2025 | -18.18 Mn |
| Sep 30, 2025 | -19.27 Mn |
| Jun 30, 2025 | -21.82 Mn |
| Mar 31, 2025 | -20.26 Mn |
| Dec 31, 2024 | -16.29 Mn |
| Sep 30, 2024 | -15.31 Mn |
| Jun 30, 2024 | -14.00 Mn |
| Mar 31, 2024 | -13.30 Mn |
| Dec 31, 2023 | -1.12 Bn |
| Sep 30, 2023 | -19.39 Mn |
| Jun 30, 2023 | -24.62 Mn |
| Mar 31, 2023 | -24.45 Mn |
| Dec 31, 2022 | -10.55 Bn |
| Sep 30, 2022 | -24.60 Mn |
| Jun 30, 2022 | -21.46 Mn |
| Mar 31, 2022 | -15.77 Mn |
| Dec 31, 2021 | -11.37 Mn |
| Sep 30, 2021 | -15.96 Mn |
| Jun 30, 2021 | -12.40 Mn |